Friulchem

About Friulchem

Friulchem S.p.A. is an Italian-based Contract Development and Manufacturing Organization (CDMO) that researches, develops, and produces semi-finished and finished products for the veterinary and human pharmaceutical sectors. Founded in 1996, the company operates as a B2B entity, partnering with major international pharmaceutical firms. The current CEO is Disma Giovanni Mazzola. The company went public via an IPO in July 2019 and is listed on the AIM Italia market.

Friulchem's business is structured into two main divisions: Animal Health and Human Health. The Animal Health unit, which represents the company's core focus and specialization, provides a range of services including micronization, granulation, blending, and spray drying. It develops and manufactures veterinary drugs, food supplements, and complementary feeds, leveraging proprietary drug delivery technologies like the patented FC-Cubes®, a highly palatable chewable format for pets. The company serves the livestock and pet markets and operates GMP-certified production facilities in Vivaro, Italy, and Magny-En-Vexin, France.

The Human Health division concentrates on developing dossiers for difficult-to-formulate generic drugs, innovative cosmeceuticals, and food supplements. While Friulchem owns the formulations for these human health products, production is typically outsourced to selected partners. The business model for this division is based on licensing these dossiers and formulations to pharmaceutical partners for worldwide distribution.

The company's revenue model relies on contract manufacturing services and licensing agreements. It identifies niche molecules, develops them into finished products or dossiers, and then partners with large pharmaceutical companies for commercialization and supply. Friulchem has established a global presence, with a significant portion of its revenue generated from exports.